EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access

MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy

Michael Thomas, Petros Christopoulos, Wade T Iams, Julien Mazières, Alexis B Cortot, Nir Peled, Gabriele Minuti, Egbert F Smit, Francois Audhuy, Karin Berghoff, S Peter Eggleton, Frank Fries und 5 weitere

Journal of Comparative Effectiveness Research · 2025

DOI: 10.57264/cer-2024-0127 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Comparative Effectiveness Research, 2025. Verfasst von Michael Thomas und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, Thoraxklinik, Heidelberg University Hospital & National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnersh…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Proto-Oncogene Proteins c-met. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim: MET exon 14 (MET ex14) skipping occurs in 3–4% of non-small-cell lung cancer (NSCLC) cases. Low frequency of this alteration necessitated open-label, single-arm trials to investigate MET inhibitors. Since broad MET biomarker testing was only recently introduced in many countries, there is a lack of historical real-world data from patients with MET ex14 skipping NSCLC receiving conventional therapies. Given the rarity of this population and limitations of existing real-world data sources, the MOMENT registry aims to prospectively collect uniform, comprehensive, high-quality data from patients with MET ex14 skipping advanced NSCLC treated in routine clinical practice, which can support clinical and regulatory decision making. Patients & methods: MOMENT is a multinational, non-interventional disease registry collecting data on patients with MET ex14 skipping advanced NSCLC receiving any systemic anticancer therapy. Newly diagnosed patients and those already receiving treatment are eligible. Patients with previous participation in a clinical trial can be included if they receive at least one subsequent therapy line in a routine clinical setting. Eligible systemic treatment includes all available anticancer therapies (approved, conditionally approved or provided through Early Access). Data collection includes biomarker testing results, demographics, baseline clinical characteristics, treatment details and effectiveness, safety information and imaging. Registry site inclusion is dependent on confirmation that local MET ex14 skipping detection methods are sufficient to confirm MET ex14 skipping status. MOMENT is currently active at more than 60 sites across Europe and North America and approximately 700 patients are expected to be enrolled within the next 4 years. The first patient was enrolled on 4 October 2022. After completion of data collection, MOMENT data can be shared with external parties to conduct non-interventional studies. Discussion/conclusion: The MOMENT registry collects comprehensive, high-quality real-world data from patients with MET ex14 skipping advanced NSCLC receiving systemic anticancer treatment in a routine clinical setting, to enable future studies informing regulatory decisions and optimal care for this rare population. Clinical Trial Registration: NCT05376891 ( ClinicalTrials.gov ); EUPAS47602 (EU PAS register no.)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungLung NeoplasmsProto-Oncogene Proteins c-metRegistriesFemaleHumansMaleMiddle AgedExonsProspective Studies

Stichwörter der Autor:innen

METex14 skippingNSCLCcancer registryreal-world datatargeted therapy

Substanzen

Antineoplastic AgentsMET protein, humanProto-Oncogene Proteins c-met

Autor:innen und Institutionen

  • Department of Thoracic Oncology, Thoraxklinik, Heidelberg University Hospital & National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ & Heidelberg University Hospital, Heidelberg, Germany;…
  • Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
  • CHU de Toulouse, Université Paul Sabatier, Toulouse, France.
  • Université de Lille, CHU Lille, CNRS, Inserm, Institut Pasteur de Lille, UMR9020 - UMR-S 1277 - Canther, F-59000 Lille, France.
  • Helmsely Cancer Center, Shaare Zedek Medical Center, Jerusalem, Israel.
  • Clinical Trial Center: Phase 1 & Precision Medicine, IRCCS, Regina Elena National Cancer Institute, 00144, Rome, Italy.

Zitieren

APA

Thomas, M., Christopoulos, P., Iams, W. T., Mazières, J., Cortot, A. B., Peled, N., Minuti, G., Smit, E. F., Audhuy, F., Berghoff, K., Eggleton, S. P., Fries, F., Hildenbrand, M., Liu, P., Mahmoudpour, S. H., Menzel, C., & Oksen, D. (2025). MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2024-0127

Vancouver

Thomas M, Christopoulos P, Iams WT, Mazières J, Cortot AB, Peled N, et al. MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy. Journal of Comparative Effectiveness Research. 2025. doi:10.57264/cer-2024-0127

BibTeX
@article{Thomas2025,
  author = {Thomas, Michael and Christopoulos, Petros and Iams, Wade T and Mazières, Julien and Cortot, Alexis B and Peled, Nir and Minuti, Gabriele and Smit, Egbert F and Audhuy, Francois and Berghoff, Karin and Eggleton, S Peter and Fries, Frank and Hildenbrand, Maike and Liu, Peter and Mahmoudpour, Seyed Hamidreza and Menzel, Christoph and Oksen, Dina},
  title = {MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2025},
  doi = {10.57264/cer-2024-0127}
}
Kostenlos starten →